Type 2 diabetes in children: Clinical aspects and risk factors

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pediatric Diabetes

Background:

• Obesity, insulin resistance, and metabolic syndrome are linked to type 2 diabetes mellitus (T2DM).
• Beta-cell dysfunction may precede impaired glucose tolerance in T2DM development.
• Distinguishing type 1 diabetes mellitus (T1DM) from T2DM presents diagnostic challenges due to shared characteristics.

Purpose of the Study:

• To highlight the subtle differences in the mechanisms of T1DM and T2DM.
• To emphasize the importance of identifying the underlying cause of diabetes mellitus for personalized treatment.
• To provide guidance on differentiating T1DM from T2DM in pediatric patients.

Main Methods:

• Review of clinical characteristics differentiating T1DM and T2DM, including autoantibody frequencies and C-peptide levels.
• Analysis of diagnostic criteria and treatment recommendations from the American Academy of Paediatrics.
• Discussion of the role of insulin resistance markers (hypertension, acanthosis, PCOS) in T2DM.

Main Results:

• T2DM patients often exhibit increased C-peptide levels, lack autoantibodies, have a family history, obesity, and signs of insulin resistance.
• T1DM patients may present with autoantibodies that can be mistaken for T2DM.
• Current pediatric guidelines recommend lifestyle modifications or metformin for blood glucose 126-200 mg/dL and HbA1c <8.5, and insulin for higher levels or ketosis.

Conclusions:

• Accurate differentiation between T1DM and T2DM is essential for appropriate management.
• Metformin is the only oral hypoglycemic approved for children, but contraindicated in ketotic patients due to lactic acidosis risk.
• Tailoring diabetes treatment based on individual mechanisms and diagnostic testing can optimize patient outcomes.